Patient Education

AbstractBackground and aimsHereditary transthyretin amyloidosis (ATTRv) should be considered in patients diagnosed with intravenous immunoglobulin (IVIg)-resistant…

AbstractBackground: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and frequently underdiagnosed cause of heart failure characterized by the…

AbstractTransthyretin cardiac amyloidosis (TTR-CA) is a pathological condition characterized by the accumulation of misfolded transthyretin (TTR) protein in the…

AbstractLight chain amyloidosis and transthyretin amyloidosis are rare protein misfolding disorders characterized by amyloid deposition in organs, varied clinical…

Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of misfolded proteins in the heart as amyloid fibrils, leading to structural and…

BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart.…

This study aimed to increase the index of suspicion for transthyretin amyloidosis (ATTR) among cardiologists leading to increased screening for amyloidosis.MethodsA…

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two…

MedStar Health was the first and among the most prominent U.S. enrollers of participants in this important global Phase III clinical trial of a new drug to treat…

Patients praised the revolutionary work of the National Amyloidosis Centre (NAC) at the Royal Free Hospital ahead of World Amyloidosis Day last week. The NAC…